ReviewGenes2023
Exploring Metabolomic Patterns in Type 2 Diabetes Mellitus and Response to Glucose-Lowering Medications-Review.
Review in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Mechanisms of Butyrate in Diabetes Through the Metabolism-Immunity Axis and Targeted Therapeutic Strategies.Molecular nutrition & food research · 2026Review
- Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.Journal of personalized medicine · 2026Review
- Effects of short-term exercise on plasma metabolic and lipidomic profiles of individuals with type 2 diabetes.Experimental physiology · 2026Article
- Grape Skin Polysaccharides Alleviate Type 2 Diabetic Rats via Gut Microbiota and Nontargeted Metabolism Alterations.Foods (Basel, Switzerland) · 2025Article
- Plasma Metabolomic Profiling Reveals Systemic Alterations in a Mouse Model of Type 2 Diabetes.Metabolites · 2025Article
- The Utility of Metabolomics in Spinal Cord Injury: Opportunities for Biomarker Discovery and Neuroprotection.International journal of molecular sciences · 2025Review
- Serum Metabolomic Profiling of Incident Type 2 Diabetes Mellitus in the Multi-ethnic Study of Atherosclerosis and Rotterdam Study.The Journal of clinical endocrinology and metabolism · 2025Article
- Metabolomics: Uncovering Insights into Obesity and Diabetes.International journal of molecular sciences · 2025Article
- Blood Metabolic Biomarkers of Diabetes Mellitus Type 2 in Aged Adults Determined by a UPLC-MS Metabolomic Approach.Metabolites · 2025Article
- Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review.Biomedicines · 2025Review
- Metabolomics analysis reveals resembling metabolites between humanized γδ TCR mice and human plasma.Scientific reports · 2024Article
- Metabolomic Profiling of Adipose Tissue in Type 2 Diabetes: Associations with Obesity and Insulin Resistance.Metabolites · 2024Article
- Metabolomic analysis of swainsonine poisoning in renal tubular epithelial cells.Frontiers in veterinary science · 2024Article
- Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes.Frontiers in pharmacology · 2024Review
- Nursing interventions guided by the theory of stress and adaptation improve the self-management ability of T2DM patients.American journal of translational research · 2024Article
- α-methyltryptophan-mediated protection against diabetic nephropathy inFrontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spectrum of information related to precision medicine in diabetes generally includes clinical data, genetics, and omics-based biomarkers that can guide personalized decisions on diabetes care. Given the remarkable progress in patient risk characterization, there is particular interest in using molecular biomarkers to guide diabetes management. Metabolomics is an emerging molecular approach that helps better understand the etiology and promises the identification of novel biomarkers for complex diseases. Both targeted or untargeted metabolites extracted from cells, biofluids, or tissues can be investigated by established high-throughput platforms, like nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques. Metabolomics is proposed as a valuable tool in precision diabetes medicine to discover biomarkers for diagnosis, prognosis, and management of the progress of diabetes through personalized phenotyping and individualized drug-response monitoring. This review offers an overview of metabolomics knowledge as potential biomarkers in type 2 diabetes mellitus (T2D) diagnosis and the response to glucose-lowering medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.